29 citations
,
September 2017 in “Oncology and therapy” The document provides advice on how to recognize and treat skin-related side effects of cancer drugs known as EGFR inhibitors.
September 2022 in “XXXIX Congresso Brasileiro de Reumatologia” Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.
October 2021 in “Revista Medicina Cutánea Ibero-Latino-Americana” PRIDE syndrome helps identify skin side effects from EGFR inhibitors like erlotinib.
21 citations
,
July 2011 in “Journal of the American Academy of Dermatology” A man developed a rash similar to pityriasis rubra pilaris after starting sorafenib for cancer, possibly due to the drug's effect on skin cells.
March 2003 in “Oncology Times” Further research is needed to develop effective cancer prevention strategies.
Keratinocytes can reverse the effects of the GNAQ oncogene, inhibiting melanoma cell growth.
8 citations
,
August 1987 in “The Journal of Dermatology” BKN-1 antibody targets specific keratin in basal cell epithelioma and normal skin basal cells.
138 citations
,
March 2021 in “Journal of the American Academy of Dermatology” Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.
May 2011 in “Psychiatric News” Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.
2 citations
,
June 2024 in “Dermatology” Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.
January 2002 in “映像情報メディア学会技術報告” Some prostate cancers have gene changes that may affect treatment with certain drugs.
5 citations
,
January 2021 in “Inflammatory Bowel Diseases” Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
143 citations
,
May 2002 in “PubMed” LGD1069 effectively prevents breast tumors in mice without toxicity.
August 2025 in “JEADV Clinical Practice” PRIDE complex side effects from EGFR inhibitors can be managed without stopping treatment.
September 2023 in “International Journal of Trichology” Tofacitinib helped a woman regrow hair with no major side effects.
5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
38 citations
,
December 2009 in “Therapeutic Advances in Medical Oncology” The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.
April 2023 in “Journal of the American Academy of Dermatology” Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.
114 citations
,
July 2003 in “PubMed” Lack of KSR1 stops certain skin tumors in mice.
August 2021 in “Revista Colombiana de Reumatología/Revista Colombiana de Reumatologia” Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.
June 2021 in “Research Square (Research Square)” Adverse events in lung cancer treatments increase fear, anxiety, and depression, with newer therapies causing fewer side effects.
35 citations
,
February 2002 in “Journal of Radiological Protection” Caffeine reduces radiation skin damage but doesn't affect tumor treatment.
53 citations
,
June 1993 in “Proceedings of the National Academy of Sciences of the United States of America” LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.
Baricitinib helps regrow hair in teens with severe alopecia areata.
17 citations
,
January 2015 in “MedChemComm” New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.
August 2025 in “Pharmaceutics” A new method improves betulin delivery and shows promise in cancer treatment.
133 citations
,
May 2016 in “Cell Host & Microbe” Human dermal fibroblasts are the main cells targeted by a virus that can cause a deadly skin cancer, and a certain inhibitor can effectively block this infection.
Bempikibart may help regrow hair in people with alopecia areata.
68 citations
,
January 2014 in “Dermatology research and practice” Skin side effects from cancer drugs targeting EGFR can affect treatment adherence but can be managed with antibiotics like tetracycline.
Cepharanthine and tetrandrine show promise as COVID-19 drugs.